HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Purchase Of Bristol OTCs Has Excedrin Written All Over It

This article was originally published in The Tan Sheet

Executive Summary

Novartis will enter the U.S. over-the-counter analgesics market with Excedrin as part of the purchase of Bristol-Myers Squibb's OTC portfolio

You may also be interested in...

New Products In Brief

Listerine anticavity: New Listerine Tooth Defense contains fluoride to "strengthen tooth enamel and protect against caries," McNeil announces. The mouthwash helps decrease caries at the root surface and enamel crown, inhibits the demineralization of enamel and enhances mineralization, McNeil claims. Available in Mint-Shield flavor, the product will carry suggested retail prices of $3.29 to $5.89. Although Tooth Defense kills germs that cause oral malodor, it is "not intended to help prevent or reduce plaque and gingivitis," the company notes. Johnson & Johnson picked up the brand after it closed its Pfizer Consumer Healthcare acquisition in December for $16.6 bil. in cash (1"The Tan Sheet" Jan. 1, 2007, In Brief). J&J divested its ACT fluoride mouth rinse to Chattem Jan. 2 in conjunction with the Pfizer acquisition (2"The Tan Sheet" Feb. 19, 2007, p. 10)...

Novartis OTC Division Is “Fastest Growing” Among Industry Leaders – CEO

Novartis Consumer Health showed "strong performance" in 2006 with full year net sales of $7.53 billion, according to earnings results announced during a fourth-quarter and year-end call Jan. 18

Novartis Sees OTCs As Crucial In Emerging – And Emerged – Global Markets

Over-the-counter and generic drugs will benefit "disproportionately" compared with prescription drugs in emerging global markets, according to Novartis Head of Corporate Mergers & Acquisitions Nayan Gregory Parekh, PhD

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts